Nabriva Therapeutics AG Stock News

Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities w

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiot

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn

Source: iQoncept / Shutterstock Nabriva Therapeutics (NASDAQ: NBRV ) stock caught the attention of traders on Friday after shares surged in price this morning. However, not all is as it seems.

Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know  appeared first on Penny Stocks to Buy, Picks, News and Information

Nabriva Therapeutics (NBRV) announces it will effect a 1-for-25 reverse stock split. These are the details.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of

Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Dan Dolan - CFO Ted Schroeder - CEO Conference Call Participants Carl Byrnes - No

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age

Nabriva Therapeutics plc (NASDAQ:NBRV ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Christi